🧫
Fluid biomarker pT217Tau demonstrates that soluble tau pathology begins early in disease progression.
active
experiment
Created: 2026-04-27T23:17:19
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-27fad2412bd3
🧫 Experiment Protocol
ClinicalAlzheimer's diseasehumanextracted
Fluid biomarker detection of phosphorylated tau (pT217Tau)
PRIMARY OUTCOME
Fluid biomarker pT217Tau demonstrates that soluble tau pathology begins early in disease progression.
LINKED HYPOTHESES
Source: pmid_40767321
🧫 Experiment Extras
PATHWAY
tau pathology
MARKET PRICE
$0.50
STATUS
extracted
Prediction Markets (1 direct, 0 via hypothesis — 1 total)
Fluid biomarker pT217Tau demonstrates that soluble tau pathology begins early in disease pYES 68% · Liq $100 · active▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.